Phase to Phase - The Guide to Drug Development
Sponsored by Thermo Fisher Scientific and PPD, experts will present innovative strategies in outsourcing discovery that allows small companies to focus on their core discovery needs and frees them up from both a capital and manpower investment.
Session Topic: Phase 3 Clinical Trials: The Real Test
- Final stage gate for clinical development of a new treatment to ensure efficacy and larger exposure to assess safety
- Typically involve 300-3,000 patients with a timeline of 1-3 years and costs millions of dollars
- Successful Phase 3 trials provide critical evidence for regulatory approval
Speakers:
- Jill Parris, Senior Director, Clinical Science, PPD, part of Thermo Fisher Scientific
- Nikolay Stoyanov, Senior Director Clinical Science, PPD, part of Thermo Fisher Scientific
- Margaret (Meg) Twomey, Director, Clinical Science, PPD, part of Thermo Fisher Scientific
- Ian Mulrenin, Associate Clinical Scientist, PPD, part of Thermo Fisher Scientific
Moderator: Danko Dominis, MD, PhD, Regional Medical Officer, PPD, part of Thermo Fisher Scientific
Refund/cancellation policy: This program is offered free of charge. As such refunds are not applicable. Questions: Contact Lauren Boyle, [email protected]
